The presence of residual tumor cells in the trigone and urethra after robot-assisted radical cystectomy (RARC) is associated with a higher tumor stage, positive margins, and cancer recurrence compared ...

Deaths among hospitalized patients with bladder cancer in the United States significantly increased from 4.5% in 2008 to 4.9% in 2021, driven by increased mortality among specific subgroups, ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

The promotional effort from Ferring features bladder cancer survivors sharing the news of a new treatment option.

Cretostimogene is an oncolytic immunotherapy with dual mechanism of action: viral replication leading to tumor lysis and release of granulocyte-macrophage colony stimulating factor.

Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG ...

Q4 2024 Earnings Call Transcript March 27, 2025 Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.62, expectations were $-0.7. Operator: Greetings, and welcome to the Relmada ...

The news from Buckingham palace was shocking. Over a year after King Charles had announced that he had been diagnosed with ...

Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive ...

The median duration of response (DOR) exceeds 28 months and is ongoing, demonstrating the durability of cretostimogene's ...

Learn more about the role of Tuberculosis in cancer and how a simple vaccine supports the immune system to fight it.

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...